• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Combination therapy with tofacitinib improves response in rheumatoid arthritis

bys25qthea
August 19, 2013
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Patients with rheumatoid arthritis (RA) taking tofacitinib in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) demonstrated an improvement in disease activity when compared to placebo.  

Evidence Rating Level: 1 (Excellent)       

Study Rundown:  Many patients with RA do not have adequate improvement in their disease activity despite treatment with currently available non-biologic DMARDs.  Tofacitinib is a novel Janus Kinase (JAK) inhibitor introduced for the treatment of RA.  In this randomized, placebo-controlled trial, the safety and efficacy of tofacitinib was evaluated as an additional therapy in patients with inadequate response to stable therapy with non-biologic DMARDs. The study randomized the patients to three treatment arms:  (1) placebo, (2) 5mg tofacitinib or (3) 10mg tofacitinib.  At 6 months, results showed a significant improvement in disease activity as well as reduced disability in both treatment arms associated with both tofacitinib groups compared to placebo:  21.4% and 25.8% treatment difference in the 5mg and 10mg tofacitinib groups compared to placebo, respectively.  No significant difference in adverse events was noted between the study arms, although tofacitinib was associated with a decrease in neutrophil count, an increase in low-density lipoprotein (LDL) levels and an increase in liver transaminases.  As most of the patients were taking methotrexate, a major limitation of this study is that it lacks the power to fully examine the efficacy of combination treatment of tofacitinib and other non-biologic DMARDs.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

In-Depth [randomized, placebo-advanced study]: This study randomly assigned 795 patient with RA to two placebo arms (n=159) advanced to 5/10mg tofacitinib twice daily or two experimental arms (n=633) directly to 5 or 10mg twice daily.  Non-responder placebo patients were advanced to treatment group at 3 months, and all other placebo patients were advanced at 6 months.  Primary end points, measured at 6 months, were rates of improvement, measured by ACR20, rates of remission (defined by Disease Activity Score for 28-joint counts based on the ESR (DAS28-4[ESR]) <2.6, and disability, defined by HAQ-DI.  Among patients receiving 5 and 10mg tofacitinib, 52.1% (p<0.001) and 56.6% (p<0.001), respectively, responded to treatment by ACR20, compared to 30.8% in the placebo group.  Similarly, tofacitinib-treated patients had a 0.44 (5mg, p<0.001) and 0.53 (10mg, p<0.001) reduction from baseline HAQ-DI, compared to 0.16 in the placebo group.  Finally, the proportion of patients with DAS28-4(ESR)<2.6 treated with tofacitinib increased to 8.5% (5mg, p=0.0038) and 12.5% (10mg, p<0.001), compared to 2.6% in the placebo group.  No statistically significant difference in adverse or serious adverse events was detected between tofacitinib and placebo treatments, although tofacitinib treatment was associated with a decreased neutrophil count, -0.75×109 (5mg) and -0.99 x109 (10mg), an increase in LDL levels, 15.65% (5mg) and 18.26% (10mg), and an increase in AST (23.5% [5mg] and 29.4% [10mg] >ULN, compared to 13.8% with placebo) and ALT (27.9% [5mg] and 34.2% [10mg] >ULN, compared to 17.6% with placebo).

RELATED REPORTS

2 Minute Medicine Rewind January 9, 2023

Daily low dose aspirin may be associated with increased fall risk for geriatric patients

2 Minute Medicine Rewind November 14, 2022

By Sai Folmsbee and Aimee Li, MD

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: geriatricsrheumatoid arthritistofacitinib
Previous Post

Healthy diet delays development, progression of chronic kidney disease in diabetics

Next Post

Home-based intervention reduces depressive symptoms in older African Americans

RelatedReports

Post-surgical wound complications more common in obese ovarian cancer patients
Weekly Rewinds

2 Minute Medicine Rewind January 9, 2023

January 11, 2023
Cardiology

Daily low dose aspirin may be associated with increased fall risk for geriatric patients

November 17, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Weekly Rewinds

2 Minute Medicine Rewind November 14, 2022

November 14, 2022
Cardiology

No difference between warfarin or dabigatran for cognitive outcomes in geriatric populations

November 4, 2022
Next Post
Home-based intervention reduces depressive symptoms in older African Americans

Home-based intervention reduces depressive symptoms in older African Americans

Childhood migraine associated with infantile colic

EMR tool may aid in diagnosis and management of ADHD

Pre-operative transcranial magnetic stimulation useful for language mapping

Highest recurrence risk of autism spectrum disorders seen among full-siblings

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options